<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173793</url>
  </required_header>
  <id_info>
    <org_study_id>AK102-201</org_study_id>
    <nct_id>NCT04173793</nct_id>
  </id_info>
  <brief_title>A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of AK102 in Patients With Heterozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AD Pharmaceuticals Co., Ltd. (Guangzhou)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the
      safety and efficacy of AK102 in patients with heterozygous familial hypercholesterolemia
      (HeFH).The primary objective of this study is to evaluate the efficacy of AK102 in patients
      with HeFH.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 12</measure>
    <time_frame>At baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in high-density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non High-density lipoprotein (non-HDL) cholesterol</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in serum Triglyceride (TG) cholesterol</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apolipoprotein A-I (ApoA-I)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Lipoprotein(a) [Lp-(a)]</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Total Cholesterol(TC)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of AK102</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
    <description>The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Heterozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>AK102 450 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK102</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>AK102 150 mg</arm_group_label>
    <arm_group_label>AK102 300 mg</arm_group_label>
    <arm_group_label>AK102 450 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins and/or Ezetimibe</intervention_name>
    <description>Lipid-lowering therapies</description>
    <arm_group_label>AK102 150 mg</arm_group_label>
    <arm_group_label>AK102 300 mg</arm_group_label>
    <arm_group_label>AK102 450 mg</arm_group_label>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with heterozygous familial hypercholesterolemia diagnosed by genetic
             confirmation or clinical diagnosis criteria.

          -  Stable on pre-existing, lipid-lowering therapies (statins with or without ezetimibe)
             for at least 4 weeks with no planned medication or dose change for the duration of
             study participation.

          -  Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 70 mg/dL in patients with
             history of Atherosclerotic Cardiovascular Disease (ASCVD) or Fasting Low-Density
             Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL in patients without history of
             Atherosclerotic Cardiovascular Disease (ASCVD).

          -  Fasting triglycerides ≤ 400 mg/dL.

          -  Body weight ≥ 40kg.

        Key Exclusion Criteria:

          -  Subjects with homozygous FH (clinically or by genotyping).

          -  Receipt of LDL apheresis within 12 months prior to the first dose of Investigational
             product.

          -  Receipt of Lomitapide or Mipomersen within 5 months prior to the first dose of
             Investigational product.

          -  Prior use of PCSK9 inhibitors.

          -  Creatine kinase (CK) ＞3 times of the upper limit of normal (ULN).

          -  Aspartate Aminotransferase (AST) ≥ 2 x ULN.

          -  Estimated Glomerular Filtration Rate (eGFR)≤ 30 mL/min/1.73m^2.

          -  Thyroid-Stimulating Hormone (TSH)&gt; 1.5 x ULN or &lt;1 x LLN.

          -  Type 1 diabetes, or type 2 diabetes that is or poorly controlled（HbA1c&gt; 8.5%).

          -  Subjects with untreated or active chronic hepatitis B or active hepatitis C virus
             infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuyang Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yujie Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Liu</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yujie Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peipei Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shuyang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HeFH</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

